Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
Mice were immunized either with unadjuvanted seasonal trivalent influenza vaccine (TIV) or TIV formulated with Vaxfectin, a cationic lipid-based adjuvant. Increasing doses of Vaxfectin resulted in increased hemagglutination-inhibition or anti-TIV ELISA antibody titers, with up to a 200-fold increase obtained with 900 microg of Vaxfectin. A >or=10-fold dose-sparing effect was demonstrated with Vaxfectin formulations. Vaxfectin preferentially increased IgG2 titers compared to IgG1 titers, resulting in a balanced IgG isotype distribution. Lower doses of Vaxfectin (30 microg) did not enhance antibody responses, but increased the number of IFN-gamma secreting T-cells by up to 18-fold. The data demonstrate that Vaxfectin enhances Th1 responses with protein-based seasonal influenza vaccine, and suggest that cellular or humoral immune responses may be preferentially induced by modifying the Vaxfectin:antigen ratio in the vaccine formulation.
Hartikka
Jukka
J
Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121-4340, USA. jhartikka@vical.com
Bozoukova
Vesselina
V
Yang
Catherine K
CK
Ye
Ming
M
Rusalov
Denis
D
Shlapobersky
Mark
M
Vilalta
Adrian
A
Wei
Qun
Q
Rolland
Alain
A
Smith
Larry R
LR
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D000956:Antigens, Viral / Q000276:immunology; D002412:Cations / Q000276:immunology / Q000494:pharmacology; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006385:Hemagglutination Inhibition Tests; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D002412:Cations; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D010714:Phosphatidylethanolamines; C460866:vaxfectin; D007371:Interferon-gamma